lunes, 26 de octubre de 2026

A treatment proven across treatment settings in HER2+ BC PHESGO: Proven efficacy and tolerability across neoadjuvant, adjuvant and 1L metastatic HER2+ BC

https://global.phesgo-hcp.com/phesgo-adjuvant.html?cid=na6625858117&utm_source=medscape&utm_medium=na&utm_campaign=her2_2026&utm_content=tx%3Aphesgonc4%3A2609%3Axx&dclid=CjkKEQjw9PvWBhDhufDs_OSRp50BEiQAAIAN_vdVZkKar_289aARnzXm81HtdB6j0jnJkHfcsGiHfdjw_wcB&gad_source=7

No hay comentarios:

Publicar un comentario